Headlands Technologies LLC Boosts Stake in Genmab A/S (NASDAQ:GMAB)

Headlands Technologies LLC grew its holdings in shares of Genmab A/S (NASDAQ:GMAB) by 1,702.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,138 shares of the company’s stock after purchasing an additional 4,853 shares during the period. Headlands Technologies LLC’s holdings in Genmab A/S were worth $129,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Capital International Investors lifted its holdings in shares of Genmab A/S by 7.8% during the 1st quarter. Capital International Investors now owns 4,373,277 shares of the company’s stock valued at $130,805,000 after purchasing an additional 315,355 shares during the last quarter. Harding Loevner LP increased its position in shares of Genmab A/S by 2.7% in the 4th quarter. Harding Loevner LP now owns 3,289,895 shares of the company’s stock valued at $97,569,000 after acquiring an additional 85,665 shares during the period. First Trust Advisors LP increased its position in shares of Genmab A/S by 16.0% in the 4th quarter. First Trust Advisors LP now owns 1,270,095 shares of the company’s stock valued at $40,440,000 after acquiring an additional 175,292 shares during the period. DDD Partners LLC acquired a new position in shares of Genmab A/S in the 2nd quarter valued at $8,860,000. Finally, Ingalls & Snyder LLC increased its position in shares of Genmab A/S by 29.3% in the 2nd quarter. Ingalls & Snyder LLC now owns 229,700 shares of the company’s stock valued at $5,772,000 after acquiring an additional 52,117 shares during the period. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. BTIG Research upped their target price on Genmab A/S from $46.00 to $47.00 and gave the company a “buy” rating in a research report on Thursday, June 27th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research report on Friday. Royal Bank of Canada raised Genmab A/S from a “sector perform” rating to an “outperform” rating in a research report on Monday, July 15th. Morgan Stanley reaffirmed an “equal weight” rating and set a $31.00 price target on shares of Genmab A/S in a research report on Wednesday, September 11th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Genmab A/S in a research report on Tuesday, August 20th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $45.20.

Genmab A/S Stock Up 1.5 %

NASDAQ:GMAB opened at $26.90 on Monday. The stock has a market capitalization of $17.79 billion, a PE ratio of 22.42, a price-to-earnings-growth ratio of 0.81 and a beta of 0.99. Genmab A/S has a 52 week low of $24.53 and a 52 week high of $38.80. The stock’s 50-day moving average price is $27.25 and its 200-day moving average price is $28.06.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Thursday, August 8th. The company reported $0.22 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.07). The company had revenue of $779.50 million during the quarter, compared to analysts’ expectations of $734.60 million. Genmab A/S had a net margin of 29.06% and a return on equity of 17.48%. Sell-side analysts expect that Genmab A/S will post 1.27 earnings per share for the current fiscal year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.